Form 4: SpringWorks Therapeutics Chief Scientific Officer Disposes of Shares and Equity Awards Following Merger with Merck KGaA

SpringWorks Therapeutics' Chief Scientific Officer, Lin Tai-An, has reported the disposition of all common stock, restricted stock units, performance share units, and stock options following the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.

Summary

• Reporting Person Lin Tai-An, Chief Scientific Officer of SpringWorks Therapeutics, Inc. (SWTX), disposed of all beneficial ownership in the company.
• The disposition occurred on July 1, 2025, as a result of the merger of SpringWorks Therapeutics with EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.
• Under the merger agreement, each outstanding share of SpringWorks common stock was cancelled and converted into the right to receive $47.00 in cash.
• Lin Tai-An disposed of 33,039 shares of common stock, which included 26,553 shares underlying restricted stock units (RSUs).
• Additionally, 8,661 performance share units (PSUs) were disposed of.
• Stock options with exercise prices of $22.8, $38.4, and $43, totaling 110,246 options (75,000 + 15,000 + 20,246), were also disposed of.
• Vested and unvested RSUs, PSUs, and stock options were converted into cash-based awards or payments based on the $47.00 merger consideration, with certain unvested tranches subject to continued employment and accelerated vesting on the nine-month anniversary of the merger closing.
• Options with an exercise price greater than $47.00 were cancelled for no consideration.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person and shareholders who received cash for their shares, as the merger completed as planned. The conversion of equity awards into cash-based awards with continued vesting and partial acceleration is also a favorable outcome for the executive. The cancellation of out-of-the-money options is a minor negative but expected.

Positives

• The merger provides a clear cash exit for shareholders at $47.00 per share.
• Equity awards (RSUs, PSUs, options) held by the Chief Scientific Officer were converted into cash-based awards or payments, providing liquidity or continued value based on the merger consideration.
• A portion of unvested equity awards will accelerate vesting (50% on the nine-month anniversary of closing) subject to continued employment, providing an incentive for key personnel retention.

Negatives

• SpringWorks Therapeutics common stock is no longer publicly traded, as it became a wholly owned subsidiary of Merck KGaA, removing it as an independent investment opportunity.
• Stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no value, resulting in a loss for holders of those specific options.

Risks

• The document does not explicitly state new risks, but the completion of the merger means the risks associated with SpringWorks Therapeutics as an independent public entity are now absorbed by Merck KGaA.
• For the reporting person, continued vesting of some cash-based awards is contingent on continued employment with Parent (Merck KGaA).

Future Outlook

The document primarily reports a past transaction (the merger completion) and its immediate effects on the reporting person's equity holdings. It indicates that certain unvested cash-based equity awards will continue to vest post-merger, with a partial acceleration on the nine-month anniversary of the closing date, contingent on continued employment with Merck KGaA.

Industry Context

This transaction represents a significant consolidation in the biotechnology and pharmaceutical sector, where larger pharmaceutical companies like Merck KGaA acquire innovative smaller biotechs like SpringWorks Therapeutics to expand their pipeline and market presence. Such mergers are common strategies for growth and diversification in the highly competitive drug development landscape.

Comparison to Industry Standards

• This Form 4 reports a specific insider transaction related to a merger, not the financial performance of the company against industry benchmarks.
• The $47.00 per share merger consideration would typically be evaluated against SpringWorks' historical stock price, analyst price targets, and comparable M&A transactions in the biotech sector at the time the merger agreement was announced (April 27, 2025). However, this document does not provide the necessary context for such a comparison.

Stakeholder Impact

• Shareholders: Received $47.00 cash per share, providing a liquidity event and a premium over the pre-merger announcement price.
• Employees (including reporting person): Equity awards converted to cash-based awards, with continued vesting contingent on employment with the acquiring entity (Merck KGaA), providing retention incentives.
• Company (SpringWorks Therapeutics): Ceased to be an independent public entity, becoming a wholly owned subsidiary of Merck KGaA, integrating its operations and pipeline into a larger pharmaceutical company.

Next Steps

• Continued employment of Lin Tai-An with Merck KGaA for vesting of remaining cash-based equity awards.
• Vesting of 50% of each then-unvested tranche of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards on the nine-month anniversary of the merger closing date.

Key Dates

Recommendation

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, SEC Form 4, Beneficial Ownership, Equity Awards, Restricted Stock Units, Performance Share Units, Stock Options, Chief Scientific Officer, Corporate Action, Biotechnology, Pharmaceuticals